Applied Molecular Transport Inc. (NASDAQ:AMTI) Director David Lamond bought 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 6th. The shares were purchased at an average cost of $42.00 per share, with a total value of $1,050,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Shares of AMTI opened at $55.70 on Thursday. The business’s 50-day moving average is $59.19 and its two-hundred day moving average is $39.99. Applied Molecular Transport Inc. has a fifty-two week low of $17.05 and a fifty-two week high of $78.22.
Applied Molecular Transport (NASDAQ:AMTI) last announced its quarterly earnings results on Thursday, March 18th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.10. On average, analysts expect that Applied Molecular Transport Inc. will post -3 EPS for the current year.
AMTI has been the subject of several analyst reports. SVB Leerink increased their price objective on Applied Molecular Transport from $32.00 to $74.00 and gave the company an “outperform” rating in a report on Thursday, February 25th. Zacks Investment Research downgraded shares of Applied Molecular Transport from a “hold” rating to a “sell” rating in a report on Wednesday, February 24th. Jefferies Financial Group lifted their target price on shares of Applied Molecular Transport from $38.00 to $75.00 in a research note on Tuesday, March 23rd. Finally, JMP Securities started coverage on shares of Applied Molecular Transport in a report on Tuesday, March 23rd. They issued an “outperform” rating and a $92.00 price target for the company. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Applied Molecular Transport currently has an average rating of “Buy” and an average target price of $68.75.
Applied Molecular Transport Company Profile
Applied Molecular Transport Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications.
Receive News & Ratings for Applied Molecular Transport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Molecular Transport and related companies with MarketBeat.com's FREE daily email newsletter.